Proteomics

Dataset Information

0

Quantitative proteome analysis of hepatocellular carcinoma tissue


ABSTRACT: Hepatocellular carcinoma (HCC) is one of the most aggressive tumors and the treatment outcome of this disease is improved when the cancer is diagnosed at early stages. This requires biomarkers allowing for an accurate and early tumor diagnosis. To identify potential markers for such applications we performed a label-free proteome analysis using samples collected from 19 patients. We analyzed the data considering events known to take place in early events of HCC development such as abnormal regulation of Wnt/b-catenin and activation of receptor tyrosine kinases (RTKs). We expected that such analysis can lead to the identification of potential biomarkers for early-stage HCC diagnosis. 31 proteins functionally linked to downstream interactors of Wnt/b-catenin and parts of RTKs´-activated pathways Ras and JAK/STAT were selected for verification in a larger and independent cohort (n= 31) using selected (multiple) reaction monitoring (SRM/MRM).

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Liver

DISEASE(S): Hepatocellular Carcinoma

SUBMITTER: Wael Naboulsi  

LAB HEAD: Barbara Sitek

PROVIDER: PXD002171 | Pride | 2016-04-13

REPOSITORIES: Pride

altmetric image

Publications

Quantitative Tissue Proteomics Analysis Reveals Versican as Potential Biomarker for Early-Stage Hepatocellular Carcinoma.

Naboulsi Wael W   Megger Dominik A DA   Bracht Thilo T   Kohl Michael M   Turewicz Michael M   Eisenacher Martin M   Voss Don Marvin DM   Schlaak Jörg F JF   Hoffmann Andreas-Claudius AC   Weber Frank F   Baba Hideo A HA   Meyer Helmut E HE   Sitek Barbara B  

Journal of proteome research 20151218 1


Hepatocellular carcinoma (HCC) is one of the most aggressive tumors, and the treatment outcome of this disease is improved when the cancer is diagnosed at an early stage. This requires biomarkers allowing an accurate and early tumor diagnosis. To identify potential markers for such applications, we analyzed a patient cohort consisting of 50 patients (50 HCC and 50 adjacent nontumorous tissue samples as controls) using two independent proteomics approaches. We performed label-free discovery analy  ...[more]

Similar Datasets

| E-GEOD-63643 | biostudies-arrayexpress
2019-09-27 | GSE137787 | GEO
2019-09-27 | GSE137784 | GEO
2019-03-29 | PXD013095 | Pride
2019-10-23 | PXD010085 | Pride
2016-09-27 | PXD003552 | Pride
| PRJNA314341 | ENA
| E-GEOD-50859 | biostudies-arrayexpress
| E-GEOD-42512 | biostudies-arrayexpress
2022-10-01 | GSE165985 | GEO